This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
by Kinjel Shah
J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
pharmaceuticals
Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?
by Kinjel Shah
PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.
pharmaceuticals
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
by Zacks Equity Research
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
biotechnology biotechs medical pharmaceuticals
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3
by Sundeep Ganoria
ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.
biotechs earnings medical pharmaceuticals
Top 3 Genomics Stocks to Consider for Your Portfolio
by Ekta Bagri
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
biotechnology gene-editing genetics genomics medical pharmaceuticals
The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum
by Zacks Equity Research
Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.
pharmaceuticals
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.
biotechnology biotechs medical pharmaceuticals
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
by Zacks Equity Research
SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.
biotechs gene-editing gene-therapy medical pharmaceuticals
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
by Zacks Equity Research
BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.
biotechnology biotechs medical pharmaceuticals
Take the Zacks Approach to Beat the Markets: Macy's, United Natural Foods & Monster Beverage in Focus
by Santanu Roy
Macy's climbs after a Zacks upgrade as multiple portfolios showcase strong gains across UNFI, Monster Beverage and other standout stocks.
construction consumer-staples industrial-products medical pharmaceuticals precious-metals retail